Your browser doesn't support javascript.
loading
Strategy for the Elimination of Hepatitis C in Cantabria.
Crespo, Javier; Tejerina Puente, Ana; Cuadrado, Antonio; Llerena, Susana; Cabezas, Joaquín.
Afiliación
  • Crespo J; Aparato Digestivo, Hospital Universitario Marqués de Valdecilla, 39002.
  • Tejerina Puente A; Servicio Cántabro de Salud.
  • Cuadrado A; Aparato Digestivo, Hospital Universitario Marqués de Valdecilla.
  • Llerena S; Aparato Digestivo, Hospital Universitario Marqués de Valdecilla, España.
  • Cabezas J; Aparato Digestivo, Hospital Universitario Marqués de Valdecilla, España.
Rev Esp Enferm Dig ; 112(7): 565-570, 2020 Jul.
Article en En | MEDLINE | ID: mdl-32543873
ABSTRACT
The hepatitis C virus (HCV) is one of the leading causes of liver-related morbidity and mortality worldwide, affecting more than 70 million people. Approximately, between 55 % and 85 % of infected people will develop chronic HCV infection and between 15 % and 30 % of this group will develop liver cirrhosis and associated complications in the following 20-30 years. In our country, the seroprevalence of anti-HCV ranges from 0.8 to 1.2 % of adult population, while 0.2 % to 0.4 % show active HCV infection. In recent years, with the appearance of direct-acting antiviral agents (DAAs), which achieve cure rates of over 95 %, the elimination of HCV is a real possibility. In fact, in 2016 the World Health Organization (WHO) stablished a global strategy with the goal of achieving its elimination by 2030.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Hepatitis C / Hepatitis C Crónica Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Hepatitis C / Hepatitis C Crónica Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article